NEW DRUG, EMBIKHIN, TREATS MALIGNANT TUMORS, LEUKEMIA

• Document Type: CREST
• Collection: General CIA Records
• Document Number (FOIA) /ESDN (CREST): CIA-RDP80-00809A000600370816-5
• Release Decision: RIPPUB
• Original Classification: S
• Document Page Count: 2
• Document Creation Date: December 22, 2016
• Document Release Date: September 27, 2011
• Sequence Number: 816
• Publication Date: February 7, 1951
• Content Type: REPORT

Sanitized Copy Approved for Release 2011/09/27: CIA-RDP80-00809A000600370816-5
COUNTRY
SUBJECT
HOW
PUBLISHED
WHERE
PUBLISHED'
DATE
PUBLISHED
LANGUAGE
CLASSIFICATION SECRET SECRET
CENTRAL INTELLIGENCE AGENCY
INFORMATION FROM
FOREIGN DOCUMENTS OR RADIO BROADCASTS
Scientific - Medicine
Weekly newspaper
Moscow
11 Jan 1951
THIS DOCUMENT CONTAINS INFORMATION AFFECTING THE NATIONAL OFFENSE
Of THE UNITED STATES WITHIN THE MEANING Of ESPIONAGE ACT SO
U. S. C.. EI AND SE. AS AMENDED. ITS TRANSMISSION OR THE REVELATION
OF ITS CONTENTS IN ANT MANNER TO AN UNAUTHORIECD PERSON IS PRO?
NI LITLD LT LAW. REPRODUCTION OF THIS FORM IS PROHIEITED.
MeditsinskiyEabotnik.
REPORT
CD NO.
DATE OF
DATE DIST. 7 Feb 1951
NO. OF PAGES 2
SUPPLEMENT TO
REPORT NO.
THIS IS UNEVALUATED INFORMATION
NEW DRUG, EMBIIUIINA TREATS MALIGNANT TUMORS, LEUKEMIA
Prof'L. Larionov
Leningrad
In regard to new remedies used in the USSR for the treatment of
malignant tumors and cancerous conditions, it is of interest to note
that a specific sensitivity of malignant tumors to dextrarotatory
atebrin has been assumed by Prof V. V. Alpatov on the basis of his
experimental results (cf Pri..roda, Vol XXXIX, No 10, 1950, pp 22-27).
While the name Embikhin may suggest a compound which is chemically
or pharmacologically similar to atebrin, the new remedy in question
on the basis of the description given by Larionov, seems to be a sub-
stance of the nitrogen mustard class.
A new remedy, Embikhin, is being used at the Institute of Oncology of the
Academy of Medical Sciences USSR. Embikhin, which is a substance of the chloro-
ethylamine class, has been tested clinically.
The therapeutic application of Embikhin is based on the depressive, action
exerted by chloroethylamines on the process of blood formation. Use of the new
remedy is indicated primarily in hyperplasic and tumorous afflictions of the blood-
forming system, particularly leukemias and lymphogranulomatosis.
For therapeutic purposes, Embikhin is injectei intravenously in a physiolog-
ical solution, most commonly in a quantity amounting to 4-6 milligrams per in-
jection. Ten to twenty injections are made in the course of the treatment. Em-
bikhin is not completely free of undesirable e"fects; it produces/nausea or vomi-
ting in many patients after the njection. This in the majority of cases is not
an obstacle to its application, however.
SEGRET
Sanitized Copy Approved for Release 2011/09/27: CIA-RDP80-00809A000600370816-5
 Sanitized Copy Approved for Release 2011/09/27: CIA-RDP80-00809A000600370816-5
7
SECRET
Determination of the optimal single therapeutic dose for the patient, of
the number of injections, and of the intervals between them is of great impor-
tance. The method of treatment has been developed by us at the clinical divi-
sion of the Institute of Oncology under participation of the following scien-
tific collaborators: Ye. M. Kuz'mina, 0. N. Nikonova, and Ye. A. Tael'. our
method is original and is based on prolonged action of the remedy as well as
individually adapted prescription.
In the treatment of lymphogranulomatosis with Embikhin, the temperature
usually becomes normal after only two injections. The treatment of lymphade-
noses in the subleukemic stage with Embikhin gives results which are good and
last for A, sufficiently long time, In cases of an advanced stage of lymphatic
leukemia accompanied by the formation of large knots and anemia, therapy with
Embikhin is not indicated. A good effect is achieved in treating chronic mye-
loid leukemia with Embikhin.
It is very significant that Embikhin has a therapeutic effect not only in
afflictions of the blood-forming system, but also in the treatment of typical
malignant tumors.
After preliminary and clinical '-esting of the method of treating lympho-
granulomatosis and leukemia with Embikhin had been carried out in a numb-;r of
scientific and medical institutions at Moscow, Leningrad, and other cities, the
Ministry of Public Health USSR authorized the introduction of the new method
into the practice of the public health service.
SECRET
Sanitized Copy Approved for Release 2011/09/27: CIA-RDP80-00809A000600370816-5